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Objective: The Health Assessment Questionnaire is widely used for patients with inﬂammatory poly-
arthritis (IP) and its subset, rheumatoid arthritis (RA). In this study, we evaluated the progression of HAQ
scores in RA (i) by systematically reviewing the published literature on the methods used to assess
changes in functional disability over time and (ii) to study in detail HAQ progression in two large
prospective observational studies from the UK.
Methods: Data from two large inception cohorts, ERAS and NOAR, were studied to determine trajectories of
HAQ progression over time by applying latent class growth models (LCGMs) to each dataset separately. Age,
sex, baseline DAS28, symptom duration, rheumatoid factor, fulﬁlment of the 1987 ACR criteria and socio-
economic status (SES) were included as potential predictors of HAQ trajectory subgroup membership.
Results: The literature search identiﬁed 49 studies showing that HAQ progression has mainly been based on
average changes in the total study population. In the HAQ progression study, a LCGM with four HAQ
trajectory subgroups was selected as providing the best ﬁt in both cohorts. In both the cohorts, older age,
female sex, longer symptom duration, fulﬁlment of the 1987 ACR criteria, higher DAS28 and lower SES were
associated with increased likelihood of membership of subgroups with worse HAQ progression.
Conclusion: Four distinct HAQ trajectory subgroups were derived from the ERAS and NOAR cohorts. The fact
that the subgroups identiﬁed were nearly identical supports their validity. Identifying distinct groups of
patients who are at risk of poor functional outcome may help to target therapy to those who are most likely
to beneﬁt.
& 2014 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-NC-
SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).r HS Journals, Inc. This is an open
UK, UK the British United
the NIHR, UK through E&H
Grant no. 17552).
.ac.uk (S.M. Verstappen).Introduction
The Health Assessment Questionnaire (HAQ) is the most widely
used measure of function in studies of inﬂammatory polyarthritis
(IP) and its subset, rheumatoid arthritis (RA) [1,2]. Worse func-
tional disability is associated with increased cardiovascular and
all-cause mortality [3,4], joint damage [5] and work disability in
patients with IP and RA [6,7]. Functional disability is mainlyaccess article under the CC BY-NC-SA license
MedLine search
N = 1596
Manuscripts evaluated
N = 225
Excluded:
- Duplicates MedLine: N = 10
- Abstracts: N = 1167
- Reviews: N = 194
Studies fulfilling inclusion criteria:
N = 49
Fig. 1. Selection process publications.
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joint damage in patients with established disease. It is therefore
often used as an outcome measure to assess the impact of disease
over time [8–10]. Predictors of worse functional disability in the
long-term include baseline or 1-year HAQ score [11–13], older age
[12,14], female gender [12,14], disease activity [11,13–15], rheu-
matoid factor (RF) positivity or anti-citrullinated protein antibody
(ACPA) positivity [16], radiographic damage [5,13,17,18], number of
co-morbidities [10,19,20], low education [15] and low socio-
economic status (SES) [17,21,22].
Previous research has suggested that the mean HAQ score over
time is J-shaped with an initial improvement after treatment com-
mencement followed by an insidious decline in patients with early RA
[11,15,23]. However, the focus of most of these studies was on the
average change over time in the total study population calculating
mean changes in HAQ score over time or applying simple linear
regression models to determine the association between disease
duration and HAQ progression. In the last two decades, more advanced
methods have become available to measure longitudinal data, such as
repeated measurement regression analysis. However, in most studies,
the change in HAQ scores over time has been measured at the group
level. Few studies have attempted to identify subgroups deﬁned in
terms of their HAQ trajectory in IP and RA patients or considered their
validity across cohorts. In a recent study that included patients with
early RA recruited to the Early Rheumatoid Arthritis Study (ERAS) and
followed up for 10 years, latent growth mixture modelling (LGMM)
was used to determine whether the study population comprises
distinct subgroups of patients with differing trajectories of functional
disability [24]. It is important to determine if similar results can be
found in other RA populations as well. In general, identiﬁcation of
distinct groups of patients who are at risk of poor outcome may help
to target therapy to those who are most likely to beneﬁt in the clinic.
The objectives of this study were (i) to give an overview of the
methods used in the literature to assess functional disability over
time and (ii) to identify common trajectories of HAQ progression
over 15 years in two large prospective observational studies from
the UK, i.e., ERAS and the Norfolk Arthritis Register (NOAR).Methods
Systematic literature review
MEDLINE was searched to identify articles describing changes in
HAQ scores over time in patients with RA or undifferentiated
polyarthritis. The following keywords were used: (([exp Arthritis,
Rheumatoid/] OR [inﬂammatory polyarthritis.mp] OR [undifferenti-
ated arthritis.mp]) AND ([health assessment questionnaire$.mp] OR
[HAQ.mp] OR [functional.mp AND disability.mp])) NOT ([exp Arthri-
tis, Juvenile Rheumatoid/] OR [JIA.mp]) NOT ([clinical trial, phase
i/ OR clinical trial, phase ii/ OR clinical trial, phase iii/ OR clinical trial,
phase iv/ OR controlled clinical trial/ OR randomized controlled trial/]
OR [exp case reports/] OR [randomized clinical trial.mp]). The
search was limited to the years “1980–2012” and English language.
Studies were selected if they met the following inclusion criteria:
Follow-up duration/disease duration Z3years, multiple (i.e., Z3)
cross-sectional assessments of HAQ in case of cross-sectional analysis,
(M)HAQ used to measure functional disability and no intervention
study (Fig. 1 for selection procedure). References of identiﬁed reviews
and selected studies were checked for eligible articles.
HAQ trajectory study: Patients recruited to the Early Rheumatoid
Arthritis Study (ERAS) and the Norfolk Arthritis Register (NOAR)
ERAS is an inception cohort to which consecutive patients
thought to have RA by a consultant rheumatologist were recruitedfrom the outpatient clinics of nine rheumatology departments in the
UK between 1986 and 1997. Patients were included if they had a
symptom duration of less than 2 years and were disease-modifying
anti-rheumatic drug (DMARD) naive [12,25]. Patients in ERAS were
subsequently excluded if the diagnosis changed, for example,
apparent early RA evolving to classical lupus or osteoarthritis.
NOAR is a primary care-based inception cohort of patients with
early IP recruited in Norfolk, UK. Consecutive patients aged over
16 years with swelling in Z2 joints that lasted Z4 weeks were
referred via the GP or rheumatologist to NOAR between 1990 and
1994 [26,27]. This analysis included all patients who had not been
given a consultant diagnosis other than RA, undifferentiated IP,
psoriatic arthritis or post-viral arthritis to explain their symptoms.
Patients whose disease has gone into spontaneous long-term
remission (no inﬂamed joints at the 3rd or 5th anniversary and
not on disease-modifying anti-rheumatic drugs (DMARDs) or
steroids) were followed up beyond the 5th anniversary; otherwise
patients were followed up until the 5th anniversary if applicable.Clinical and laboratory assessments and socio-economic status
Standard clinical assessments were made by trained research
nurses in both studies at baseline and included date of symptom
onset and number of swollen and tender joints. RA was deﬁned
according to the 1987 ACR criteria and applied cumulatively. At
each visit, DMARD and biologics use, including start and stop date,
was recorded. The two cohorts differed in laboratory assessments.
In ERAS, routine haematology tests included the erythrocyte
sedimentation rate (ESR) measured according to Westergren test
and routine serology including RF. In NOAR, blood was collected
and stored in 801C freezers to measure RF (positive 440 mg/L)
and C-reactive protein (CRP). Due to these small differences in data
collection and visual analogue scale general well-being missing in
NOAR, the 4-component DAS28 score based on ESR values was
calculated in ERAS and the three-component DAS28 score based
on CRP was calculated in NOAR.
Socio-economic status was deﬁned as an area-level categorical
variable, based on the Index of Multiple Deprivation (IMD) 2007. In
the IMD, the UK is divided into “super output areas,” with a
minimum population of 1000 (mean 1500). Information on
income, employment, health, education, barriers to services, crime
and living environment is used to assign a deprivation score to
each super output area. These scores are then ranked across the
country. For this study, we used postal codes to assign each patient
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mined quartile of deprivation.
All patients completed the disability index of the modiﬁed
British version of the Stanford Health Assessment Questionnaire
(HAQ) [28] at baseline and at subsequent follow-up visits. The HAQ
comprises 20 questions in eight categories. A score of 0 (no
difﬁculty), 1 (some difﬁculty), 2 (much difﬁculty or need of assis-
tance) or 3 (unable to perform) is given to each question; the
highest score in each category represents the score for that category.
The sum of scores is then divided by the number of categories,
yielding a total score ranging from 0 (best) to 3 (worst). Although
patients in ERAS completed the HAQ questionnaire annually after
inclusion in the cohort, to resemble the NOAR assessment visits and
to ensure that the models were validated using as similar datasets
as possible, HAQ scores obtained at 1, 2, 3, 5, 7, 10 and 15 years after
inclusion were used for these analyses. Sensitivity analysis using all
the ERAS HAQ follow-up data indicated that this did not affect
either the number or the shape of the trajectories in the best-ﬁtting
model. Patients with missing HAQ data at baseline and a symptom
duration 42 years were excluded from the analysis.
All patients gave written informed consent and both studies
were approved by the relevant UK National Health Service
Research Ethics Committees.Statistical analysis
Baseline clinical and demographic data are described for both
the cohorts. To determine trajectories of HAQ progression over
time, latent class growth models (LCGMs) [29] were applied to the
ERAS and NOAR datasets separately and independently. The model
captures common characteristics of HAQ trajectories within a
subpopulation through latent classes. A mixture of censored
normal distributions was used to model the longitudinal HAQ
outcomes over time. A censored normal LCGM was chosen because
HAQ is a bounded score at 0 and 3. To determine the number of
trajectory subgroups, we considered several factors including
model-ﬁt statistics such as the Akaike Information Criterion
(AIC), the Bayesian Information Criterion (BIC) and the Lo–Men-
dell–Rubin likelihood ratio test. The best-ﬁtting model was then
identiﬁed, leaning towards parsimony in the number of trajectory
groups. The model is based on a joint likelihood including two
parts: an outcome model and a logistic regression model for class
membership. Several time-dependent covariates, such as linear,
quadratic, cubic and reciprocal (in ERAS) terms of year since
registration, were included in the outcome part to model the
trajectory shape within subgroups. Age, gender, baseline DAS28,
symptom duration, RF, fulﬁlment of the ACR criteria for RA and SES
were included as predictors of class membership. Odds ratios
(ORs) and 95% conﬁdence intervals (95% CI) were calculated for
each class membership group with the lowest class membership
as reference. Each patient was assigned to one of the trajectory
groups for which he/she had the highest probability of member-
ship. We also describe the percentage of patients receiving
methotrexate and the percentage of patients using biologics
during follow-up within each subgroup membership group. The
LCGM analyses were performed by using M-Plus or SAS macro
PROC TRAJ.Results of systematic literature review
Description of identiﬁed studies
A total of 49 studies were identiﬁed: 17 studies including
patients with early RA or IP (mean/median disease durationo2 years or including a group of patients with disease duration
o2 years) [8,10,13–15,30–41] and 32 studies including patients
with a disease duration of more than 2 years [19,20,42–71]
(Table 1). The follow-up duration varied between studies ranging
from a minimum of 3 years (i.e., inclusion criteria) [38,41,42,
55,58,66] to 415 years [31,33,51,57,67]. Age and gender distribu-
tion were representative of a general RA population, except in one
study in which only women were included [10].
Methods used to evaluate change in HAQ score over time
Overall, different methods were used to assess change in HAQ
score over time in both the early RA group and the established RA
group (Table 1, column 8). In 29 studies, HAQ scores were
measured cross-sectionally at more than 3 time-points following
the same study population over time or for more than 3 groups of
patients with increasing disease duration [10,13–15,30–32,34–39,
41,42,45–47,51,53–55,58,59,62,64,66,68,69]. A J-shaped trajectory
was observed in 12/14 (86%) cross-sectional studies includ-
ing patients with early disease [10,13–15,30,32,34–39,41] and in
4/9 (44%) studies including patients with established disease
[42,58,62,64].
Annual HAQ progression rates are shown in the last column of
Table 1. In eight of the 29 cross-sectional studies, change in HAQ
score was calculated by the following methods: subtracting HAQ
scores obtained at two different time-points divided by the
number of years of follow-up, calculating the median difference
from r3 years disease duration groups [51], calculating median
change during 3-year intervals [10], calculating mean change from
the ﬁrst assessment [34,37], calculating median change from 0 to
6 months and 2 until 3 years [66], calculating annualised AUC [55],
calculating the mean effect size [46] or estimating the annual
change in those with early RA and those with established RA [43].
In other studies, linear regression analysis was used to assess
the association between disease duration and (change in) HAQ
score including one time point per patient [10,15,19,31,33,44,
48,61,64,65,68,71], including multiple time-points per patient
[49,50,52,70], calculating the annual percentage reduction in
average disability [56], including all of the available study obser-
vations measured during follow-up by using a dynamic panel data
model for repeated measurements applying pooled time-series
regression analysis, generalised estimating equations (GEE)
[20,33,60,63,69,72], linear mixed-effects models with a random
effect for the repeated observations [8,67,71], marginal structural
model [40] and generalised linear models [47,60].
In a few studies, different regression models were constructed
and the best ﬁt was tested. In one study by Leigh et al. [50],
methods used in economics (Tobit, Fixed effects and dummy
variable for cohort models) were applied to address the problems
of censoring, panel data and cohort effects. In another study by
Leigh and Fries [73], six different multiple regression analyses
were performed, including individual or combinations of covari-
ates (eg, years of disease duration, years of disease duration2,
gender, education and age). Wolfe [33] constructed various group
and individual linear and non-linear (fractional polynomial)
regression models. Three main ﬁndings were observed when
analysing at a group level: (i) HAQ disability scores were already
high at disease onset; (ii) annual HAQ progression was very slow
(i.e., 0.03 units per year) and (iii) the explained variance was
only 5%. However, when including covariates to the model, the ﬁt
of the model became better and 51% of the variance could be
explained. When applying a fractional polynominal model (eg,
including HAQ score and HAQ scorefraction in the model), the
explained variance was 37%.
Overall, change in HAQ scores was mainly based on analysis in
the total study population without identiﬁcation of distinct
Table 1
Baseline demographic and clinical characteristics of previous publications
Study (country) n Age Female
gender
Disease duration Follow-up duration HAQ baseline Analysis method Progression HAQ
score
HAQ scores/change over time
van Zeben et al.
[30] (NL)
127 DR4: 34.6 (9.0) NA 1.7 (1.5) yrs 6.7 (2.2) 0.6 (0.60) Cross-sectional Mean (SD) score at
1, 4 and 8 yrs
DR4 : 0.69 (0.6); 0.50
(0.62); 0.67 (0.73). DR4þ:
0.70 (0.56); 0.88 (0.68);
1.05 (1.02)
DR4þ: 37.7 (8.0) 1.6 (1.4) yrs 6.5 (1.6) 0.70 (0.56)
Wolfe et al. [31],
(USA)
561 53.7 (14.4) 72.0 % 1.6 (0.56) yrs NA NA Cross-sectional,
least square
methodology
using all time-
points for each
patient (Figure
only)
Mean (SD) score at
ﬁrst visit: 0–2;
2–7; 7–12; 12–17
and 17–22 yrs
0.82 (0.63); 0.90 (0.61); 1.03
(0.58)55.0 (14.4) 72.7 % 6.0 (1.52) yrs
1.11 (0.63); 1.19 (0.76)55.4 (11.4) 82.1 % 11.2 (1.54) yrs
54.9 (11.9) 63.2 % 16.2 (1.53) yrs
62.5 (8.6) 80.0 % 21.3 (1.56) yrs
Guillemin et al.
[15] (NL and
FR), EURIDISS
NL ¼ 221 54.8 1.9 (M/F) o1 yrs 5 yrs 1.18 Cross-sectional
crude mean
values and mean-
adjusted values.
Multivariate
linear regression.
Mean score and per
yr increase
disease duration
(I) and disease
duration, disease
duration2 (II)
o1 yrs: 0.99 and 1.04
FR ¼ 116 53.9 2.3 (M/F) 1–2 yrs 1.05 1–2 yrs: 0.83 and 0.94
2–3 yrs 2–3 yrs: 1.22 and 1.16
3–4 yrs 3–4 yrs: 1.29 and 1.23
4–5 yrs 4–5 yrs: 1.55 and 1.43
I: β ¼ 0.10; II: β ¼ 0.13 and
β ¼ 0.022
Munro et al. [32]
(UK)
I ¼ 53 (44–60) I ¼ 75% I ¼ 0–2 yrs 5 yrs I ¼ 1.88 (1.32–2.38) Cross-sectional Median (IQR) score
at baseline and at
1, 2, 3, 4 and 5 yrs
Group I: 1.06 (0.53–1.88);
1.00 (0.13–1.38); 1.00
(0.44–1.75); 1.13 (0.63–
2.00); 1.25 (0.50–2.00),
group II: 1.13 (0.66–1.72);
1.25 (0.75–1.83); 1.27
(0.75–1.88); 1.57 (0.88–
2.25); 1.81 (1.03–2.22),
group III, 1.57 (0.97–2.22);
1.50 (1.00–2.25); 1.75
(1.13–2.38); 1.75 (0.88–
2.35); 2.13 (1.23–2.50)
II¼54 (44–64) II ¼ 85% II ¼ 42–5 yrs II ¼ 1.75 (1.19–2.25)
III¼57 [50–65] III ¼ 79% III ¼ 45 yrs III ¼ 2.00 (1.38–
2.38)
Drossaers-Bakker
et al. [10] (NL)
112 37 (8.4) 100% 1.0 (0–5) yrs Median ¼ 12
(range: 10–14)
yrs
0.75 Cross-sectional and
multiple linear
regression at
12 yrs
Median change:
0–3; 3–6 and
6–12 yrs
0 (1.89, 1); 3–6 yrs ¼ 0
(1.25, 1.29); 6–12 yrs ¼
1.3 (1.0, 2.16)
β ¼ 0.043 (95% CI: 0.01 to
0.097)
Wiles et al. [14]
(UK)
684 55 (42–68) 67% 5.9 (2.9–11.9)
months
5 yrs 0.81 (0.25–1.50) Cross-sectional at
different time-
points
Median (IQR) score
at baseline and at
1, 2, 3 and 5 yrs
0.81 (0.25–1.50); 0.50
(0.125–1.375); 0.625
(0.125–1.375); 0.625 (0.25–
1.375), 0.875 (0.25–1.625)
Wolfe [33] (US) 1843 54.6 (12.7) (S) 72% (S) 0.9 (0.5) (S) yrs 16.7 (1.09) yrs 1.08 (0.69) 1) Ordinary least- Annual change 1) 0.020 (95% CI 0.016–0.24)
squares linear 2) 0.030 (95% CI 0.027–0.034)
S: 50
regression using
one data point in
time per patient
2) GEE (all)
3) GEE (S)
3) (S) 0.020 (95% CI 0.01–
0.03)
Kroot et al. [34]
(NL)
622 53.3 (18–86) 62% o1 yr 10 yrs 0.67 (0–1.97) Cross-sectional Annual mean
scores from
baseline until 10
yrs (mean
difference from
baseline)
Baseline ¼ 0.67; 0.49
(0.25); 0.55 (0.23);
0.53 (0.24); 0.56
(0.18); 0.55 (0.19); 0.56
(0.10); 0.63 (0.01); 0.65
(0.01); 0.65 (0.07)
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Welsing et al. [8],
(NL)
378 54.8 (14.8) 63.8% o1 yr 6.29 (3.8) yrs 0.47 (0.17–1.1) Adjusted linear
mixed model
Adjusted annual
change
β ¼ 0.02 units per yr
Ahlmén et al. [35]
(SE)
W: 343 W: 54 (16) 62% o1 yr 5 yrs W: 1.05 (0.62) Cross-sectional at
different time-
points
Mean (SD) score at
baseline and at 1,
2 and 5 yrs
W: 1.05 (0.62); 0.62 (0.58);
0.65 (0.65); 0.73 (0.68)
M: 206 M: 61 (13) M: 0.84 (0.55) M: 0.84 (0.55); 0.44 (0.49);
0.47 (0.52); 0.51 (0.56)
Combe et al. [13]
(FR)
191 50.5 (14.7) 73% 3.6 (2.6) months 5 yrs 1.3 (0–2.75) Cross-sectional at
different time-
points
Mean (range) score
at baseline and at
3 yrs and 5 yrs
1.3 (0–2.75); 0.5 (0–2.5); 0.6
(0–3.0)
Benton et al. [36]
(NZ)
34 Median ¼ 48.5 62% Median ¼
4 months
6 yrs 0.33 (0–1.6) Cross-sectional at
different time-
points
Median score at
baseline and at
1 and 6 yrs
0.6; 0.16; 0.33
Persson et al. [37]
(SE)
158 52 (42–59) 64% 10 (6–14) months 4 yrs 0.92 (0.60) Cross-sectional at
different time-
points
Mean (SD) score
(mean (SD)
change from yr 1)
at 1, 2, 3, 4 and
5 yrs
0.918 (0.60); 0.843 (0.56)
[0.062 (0.43)]; 1.009
(0.60) [0.085 (0.50)]; 0.957
(0.61) [0.049 (0.49)]; 0.989
(0.57) [0.085 (0.53)]
Proudman et al.
[38] (AU)
61 56 (14) 76% 12 (6–104) weeks 36 months 0.9 (0.5) Cross-sectional at
different time-
points
Mean (SD) score at
baseline and at
12, 24 and 36
months
0.9 (0.5); 0.3 (0.4); 0.2 (0.3);
0.3 (0.4)
Courvoisier et al.
[39] (FR)
112 50.4 (12.6) 80.3% 3.9 (2.8) months 10 yrs 1.29 (0.71) Cross-sectional at
different time-
points
Mean (SD) score at
baseline and at 3,
5 and 10 yrs
1.29 (0.71); 0.53 (0.62); 0.57
(0.62); and 0.75 (0.71)
Farragher et al.
[40] (UK)
1084 53 (41–66) 65.4% 4 (2–10) months 10 yrs 0.75 (0.25–1.375) Change and
marginal
structural model
Change over 10 yrs
and annual rate,
adjusted MDIC
treated vs not
treated (T vs NT)
T: 0.24 (95% CI: 0.14–0.33)
and NT: 0.13 (95% CI: 0.05–
0.21)
Adj MDIC: -0.01 (95% CI:
0.20 to 0.19)
Benka et al. [41]
(SK)
116 47.6 (12.4) 85% 22.1 (16.1) months 3 yrs 1.15 (0.68) Cross-sectional at
different time-
points
Mean (SD) score at
baseline and at 1,
2 and 3 yrs
1.15 (0.68); 1.08 (0.66); 1.05
(0.72); 0.98 (0.74)
Disease duration 42 yrs
Fries et al. [42]
(US)
322 51 yrs NA 12 yrs 36 months 0.80 Cross-sectional at
different time-
points
Mean scores at
baseline and at 6,
12, 18, 24, 30 and
36 months
0.80; 0.78; 0.83; 0.83; 0.93;
1.11; 1.18
Sherrer et al. [43]
(US)
681 62 (13) 72% 10 (6) yrs 12 (6) yrs Cross-sectional: not
available
Mean HAQ score at
the end of the
study
Annual rate in ﬁrst
few yrs and after
15 yrs
0.10 and 0.02
Wolfe and Cathay
[44]
1274 10.3 (12) 71% 7.4 (9.11) yrs Mean ¼ 3.9 (3.31) 0.98 (0.76) Linear regression at
baseline and for
change in HAQ
after baseline
HAQ score and
change in HAQ
Baseline: β ¼ 0.013 HAQ
score per yr increase in
disease duration and
β ¼ 0.11 change HAQ score
per increase in disease
duration
Epstein et al. [45]
(US)
574 55 75% 10.2 yrs 5 yrs 1.18 Cross-sectional at
different time-
points non-gold
vs gold group:
Unadj and adj
mean score at
baseline and at 1,
2, 3, 4 and 5 yrs.
GEE only p-value
shown
Unadj: 1.30 vs 1.09; 1.24 vs
1.08; 1.30 vs 1.16; 1.32 vs
1.16; 1.41 vs 1.21; 1.14 vs
1.00; Adj: 1.18 vs 1.20; 1.24
vs 1.27; 1.25 vs 1.29; 1.35
vs 1.32; 1.08 vs 1.11
GEE
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Table 1 (continued )
Study (country) n Age Female
gender
Disease duration Follow-up duration HAQ baseline Analysis method Progression HAQ
score
HAQ scores/change over time
Hawley and
Wolfe [46]
157 50.8 (12.5) 75% 6.7 (8.2) yrs Mean ¼ 9.8 SD
0.75)
0.5 (0.5) Cross-sectional at
different time-
points
Mean (effect size
from baseline) at
baseline and at 2,
5 and 10 yrs
0.5 (NA); 0.5 (0.01); 1.3
(1.63); 1.6 (2.39)
Leigh et al. [47]
(US)
L: 209 L: 52 (14) L; 86% L: 12 (9) yrs 8 yrs L: 1.09 (0.83) Cross tabulation
(L) at follow-up
and all
(A) patients
including
deceased
Annual rate L cohort: 0.018 per yr
D: 54 D: 66 (10) D: 63% D: 18 (9) yrs D: 1.75 (0.88)
Multiple regression
pooling data
including all
time-points.
Different models
(duration,
duration2 and
duration3)
L (0–10 yrs) W vs M: 0.017 vs
0.003
L (10–20 yrs) W and M: 0.016
vs 0.010
A (0–10 yrs) W and M: 0.032
vs 0.063.
A (10–20 yrs) W and M:
0.029 vs 0.079:
Linear model: β ¼ 0.0518
Guillemin et al.
[48] (FR)
82 53.3 (17.8–89.9) 69.5% 7.2 (0–31) yrs 7.2 (0–31) yrs and
o5 yrs (mean
2.3) vs 5 yrs
(mean 14.7)
1.5 (0–3) Multiple regression
total sample and
for o5 yrs and
45 yrs disease
duration groups
Annual adjusted:
additive model
and
multiplicative
model
Total: β ¼ 0.003 (p o 0.05)
and β ¼ 0.002
(p o 0.05); o5 yrs β ¼
0.007 (NS) and 0.007 (NS)
and 45 yrs, β ¼ 0.003 (p
o 0.05) and
β ¼ 0.003 (p o 0.05)
Ward and Leigh
[49] (US)
188 Married (MA): 54.6
(11.7)
78% 13.5 (9.0) yrs 9.5 yrs 1.1 (0.8) Pooled time-series
regression
analysis
Mean-adjusted
annual rate (MA
vs UNM); all
patients; patients
with complete
follow-up; men
and women
β ¼ 0.01 vs β ¼ 0.03; β ¼
0.007 vs β ¼ 0.02; β ¼
0.006 vs β¼ 0.03; β ¼ 0.01
vs β ¼ 0.03
94 Unmarried (UNM):
54.0 (13.4)
94%
15.0 (9.2) yrs 1.3 (0.9)
Gardiner et al.
[19] (UK)
175 55.4 (range: 18–86) 82% 12.7 (range: 0–43)
yrs
5 yrs 1.77 (0.75) Multiple linear
regression
analysis using
baseline HAQ and
change over 5 yrs
Adjusted rate and
mean annual
change over 5 yrs
β ¼ 0.019 (SE 0.01) and 0.03
units/yr
Leigh et al. [50]
(US)
L: 209 L: 52 (14) L: 86% L: 12 (9) yrs L: 8 yrs L: 1.16 (0.81) Using all valid
observations
during follow-up:
Annual slope
1) Linear regression 1) β ¼ 0.014
2) Tobit regression 2) β ¼ 0.014
3) β ¼ 0.019
D: 54 D: 66 (1) D: 63% D: 18 (9) D: until last visit D: 1.75 (0.88)
3) OLS ﬁxed effects
by cohort (I ¼ 0–
9, II ¼ 9–19 and
II ¼419 yrs
disease duration
at baseline)
4) I, β ¼ 0.003; II, β ¼
0.0001; III, 0.017
LFU: 67 LFU: 55 (12) LFU: 85% LFU: 14 (9) LFU: until last visit LFU: 1.20 (0.90)
4) Cohort OLS ﬁxed
effects
5) I, β ¼ 0.0210; II, β ¼
0.0103; III, β ¼ 0.0293
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Lassere et al. [51]
(AU)
358 61. (12.7) 73.2 % 13.6 (10.4) yrs r3 yrs Median (IQR) Median difference Median difference 0.25 (0.500, 0.001);
43 to r6 yrs 0.250 (0.781) Percentile curves
using the
weighted average
method.
(95% CI) from
3 yrs: 3–6; 6–12;
12–18 and 418
yrs
NA
0.375 (0.625, 0.125);
0.625 (0.875, 0.375);
0.875 (1.125, 0.500)
NA
46 to r12 yrs 0.625 (1.188)
412 to r18 yrs 0.875 (1.25)
418 yrs 1.125 (0.75)
1.375 (1.25)
Ward et al. [52]
(US)
282 52.5 (11.7)a 84% 13.6 (9.1) yrs 10.5 (3.8) yrs 1.03 (0.8) Pooled time-series
regression
Adjusted annual rate β ¼ 0.015 (95% CI: 0.012,
0.018)a52.6 (11.4)b 77% 14.0 (8.6) yrs 10.0 (4.1) yrs 1.00 (0.8)
analysis β ¼ 0.019 (95% CI: 0.014–
0.024)b
Clarke et al. [53]
(CA)
130 62.4 (9.9) 83.1% 22.5 (10.5) yrs 45yrs 1.6 (0.7) Cross-sectional for
different disease
duration groups
At mean disease
duration: 3.8; 7.8;
12.5; 17.5, 22.2;
26.9; 36.6
1.3 (0.5); 1.2 (0.7); 1.3 (0.8);
1.4 (0.8); 1.5 (0.8); 1.5 (0.7);
1.8 (0.6)
Gordon et al.
[54]c
289 59 (19–82) 73% 10 (1–61) yrs 10 yrs 13 (0–60) Cross-sectional at
different time-
points
Median (range)
score at baseline
at 5 and 10 yrs
13 (0–60); 13 (0–60) and 23
(0–60)
Hurst et al. [55]
(US)
924 54.9 yrs 72% 6.7 yrs MTX: 3.23 (SE 0.13) 1.60 (SE 0.03) AUC ¼ (area above
baseline HAQ
Mean (SE)
annualised AUC
0.33 (0.03)
HCQ: 2.61 (SE 0.17) 1.18 (SE 0.04)
0.18 (0.03)
Gold: 1.96 (SE 0.17) 1.52 (SE 0.05) reference line) 
(area below
baseline
reference line)
averted
0.38 (0.04)
Krishnan and
Fries [56] (US)
3035 55 (14.3) 76% 4.7 (4.5) yrs 5.3 (4.3) yrs 1.03 (0.74) Generalised Least
square regression
Unadjusted and
adjusted annual
percentage
reduction
Unadj: 2.7% (2.3–3.1); Adj:
2.0% (1.8–2.2)
Ordinary least
square regression
using average
cumulative data
Unadj: 2.8% change (2.4–3.2);
Adj: 2.1 (1.7–2.5)
Krishnan et al.
[57] (US and
CA)
6436 58.5 (48.0–67.4) 74% 8.0 (2.3–16.7) yrs 20 yrs 1.13 (0.5–1.8) Percentile curves Smoothed growth
curves, men and
women
separately per
age group
See article
Demange et al.
[58] (Europe)
542 52.5 (12.1) 69% 2.1 (1.3) yrs 3 yrs 0.99 (0.71) Cross-sectional at
different time-
points
Mean (SD) score at
baseline (¼ 1 yr),
2 yrs and 3 yrs
0.99 (0.71); 0.98 (0.74); 0.99
(0.75)
Baddoura et al.
[59] (LB)
298 51.5 (14.7) 87.6% 8.9 (8.7) yrs Cross-sectional in
5 disease
duration groups
0.62 (0.65) Cross-sectional for
5 disease
duration groups
Disease duration:
o1 yr; Z1 and
o2 yrs; Z2 and
o5 yrs; Z5 and
o10 yrs; Z10 yrs
0.69 (0.64); 0.53 (0.50); 0.43
(0.45); 0.45 (0.50); 0.95
(0.80)
M-HAQ
Sokka et al. [60]
(FI)
RA: 863
C: 1176
55 70% Mean 11.3 yrs
(previous pub)
5 yrs 0.71 (0.71) Generalised linear
models
Annual rate 0.01 per yr
0.17 (0.41) 0.01 per yr
Shinozaki et al.
[61] (JP)
1265 57.9 (12.3) 81.5% 11.2 (12.3) yrs 4 yrs 0.81 (0.75) Linear regression.
Slope regression
line based on
mean value at
6 monthly
intervals
Per 6 months:
MMP3þ/RFþ;
MMP3þ/RF ;
MMP3/RFþ;
MMP3/RF
β ¼ 0.0179 (95% CI: 0.014–
0.022); β ¼ 0.016 (95% CI
0.012–0.021);
β ¼ 0.052 (95% CI:
0.002–0.033); β ¼ 0.02
(95% CI: 0.012–0.004)
Odegard et al.
[62] (NO)
149 50.2 (12.5) 76% 2.2 (1.2) yrs 10 yrs 0.86 (0.61) Cross-sectional at
different time-
points
Mean (SD) score at
1 yr, 2 yrs, 5 yrs
and 10 yrs
0.86 (0.61); 0.85 (0.62); 0.85
(0.65); 0.86 (0.60); 0.91
(0.70)
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Table 1 (continued )
Study (country) n Age Female
gender
Disease duration Follow-up duration HAQ baseline Analysis method Progression HAQ
score
HAQ scores/change over time
Iikuni et al. [70]
(JP)
CS: 55 CS: 56.6 (11.2) CS: 76.4% CS: 10.71 (11.17) yrs 4 yrs CS: 0.48 (0.61) For each patient
linear regression
analysis for all
available HAQ
data of that
individual
Mean annual rate CS: β ¼ 0.0058
NCS: 159 NCS: 55.3 (11.4) NCS: 74.2% NCS: 7.62 (6.92) yrs NCS: 0.40 (0.49) NCS: β ¼ 0.0090
Gonzalez-Alvaro
et al. [63] (ES)
789 61 (13) 72% 13 (13) yrs 4 yrs 1.2 (0.9) Fitted population-
averaged model
by weighted
estimating
equations nested
by patient and
visit
Mean annual rate 2004 vs 2000: β ¼ 0.09
(0.03 to 0.15) and adj
β ¼ 0.15 (0.07 to 0.22)
Ranganath et al.
[64] (US)
889 56 (14.6) 77% o3yrs 6–12 months 0.57 (0.5) Cross-sectional in
different disease
duration groups
Mean (SD) and
mean change
(SD) in disease
0.57 (0.5) and 0.13 (0.5);
0.47 (0.4) and 0.03 (0.4);
0.61 (0.5) and 0.07 (0.4)
56 (13.7) 75% 3–5 yrs 0.47 (0.4)
Multivariate linear
regression
analysis
duration groups:
o3 yrs, 3–5 yrs
and 45 yrs
Change in HAQ per
10 yrs increase
disease duration
β ¼ 0.027 (95% CI: 0.002–
0.052)
60 (12.0) 77% 45 yrs 0.61 (0.5)
Iikuni et al. [65]
(JP)
W: 4027 W: 57.8 (12.8) 83.5% W: 10 (5–16) yrs One time point per
patient
W: 0.63 (0.13–1.38) Multiple linear
regression
Adjusted annual
rate
W: 0.0194
M: 797 M: 60.0 (12.8) M: 8 (4–14) yrs M: 0.25 (0–0.875) M: 0.0067
Bazzani et al. [66]
(IT)
1010 55.7 (13.0) 83% 9.32 (7.3) yrs 3 yrs 1.46 (0.61) Cross-sectional at
different time-
points
Median change:
baseline to
6 months and
2nd to 3rd year
Change: 0.34 and 0.64
Wolfe and
Michaud [67]
18,485 59.9 (13.0) 76.7% 9.7 (4.4–18.1) yrs Lifetime NA Annualised lifetime
rates of
progression
Mean per yr β ¼ 0.016 (95% CI: 0.015–
0.017)10 yrs 1.06 (0.73)
Annualised
observed rates of
progression
β ¼ 0.013 (95% CI: 0.010–
0.015)
Michaud et al.
[20] (US)
18,485 60 77% 12 yrs 3.7 (3.2) yrs 1.06 (0.73) GEE, adjusted for
confounders
Overall adjusted
annual rate
0.014 (0.012–0.015)
Separate analysis
for gender, age,
education,
smoking status,
co-morbidity,
year of RA onset,
severity of
disease and
treatment
allocation
See article
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Staples et al. [68]
(AU)
1801 55.9 (12.6) 73.0% 13.0 (10.4) yrs 60 months 1.64 (0.66) (derived
from EQ-5D)
Multiple linear
regression at
baseline and
cross-sectional at
follow-up
Adjusted annual
rate
β ¼ 0.012 (95% CI: 0.009–
0.016)
Baseline and 6, 12,
18, 24, 30, 36, 42,
48, 54 and 60
months
1.64 (0.66); 1.28 (0.72); 1.14
(0.74); 1.14 (0.77); 1.14
(0.74); 1.16 (0.76); 1.14
(0.76); 1.14 (0.78); 1.16
(0.77); 1.15 (0.75); 1.24
(0.79)
Bjork et al. [69]
(SE and US)
SE: 149 SE: 56 (14) SE: 68% SE: 2.4 (0.7) yrs 5 yrs SE: 0.6 (0.6) Cross-sectional at
two time-points
and GEE
Mean (SD) score at
baseline and
0.64–0.74 (SE)
US: 86% 0.74–0.85 (USA)US: 85 US: 53 (16) US: 2.6 (4.3) yrs US: 0.8 (0.7)
5 yrs.
Adjusted slope
SE: mean 0.68 (0.58) and
USA: 0.80 (0.65) GEE
coefﬁcient 0.28 (95% CI:
0.44 to 0.13)
Shidara et al. [71]
(JP)
1226 59 (52–67) 81.6% 10 (4–16) yrs 5 yrs 0.6 (0.1–1.3) Multivariate linear
regression
Adjusted slope at
1st, 3rd and 5th
yr
Anti-CCPþ vs Anti-CCP:
1st yr (β ¼ 0.0335); 2nd (β
¼ 0.0317); 3rd yr (β ¼
0.0199)
Linear mixed model
over 5 yrs Adjusted slope
RFþ vs RF : 1st yr (β ¼
0.0004); 2nd yr (β ¼
0.0095); 3rd yr (β ¼
0.0108)
Anti-CCPþ: β ¼ 0.00657
Anti-CCP: β ¼ 0.00346
RFþ: β ¼ 0.00613
RF : β ¼ 0.00617
n ¼ number of participants; data on age, disease duration or follow-up duration are mean (SD) or median (IQR); HAQ ¼ health assessment questionnaire; M-HAQ ¼ modiﬁed HAQ; yrs ¼ years; L ¼ alive at follow-up; D ¼ died;
LFU ¼ lost to follow-up; NA ¼ not available; W ¼ women; M ¼ men; MA ¼ married; UNM ¼ unmarried; RA ¼ rheumatoid arthritis; C ¼ control; CS ¼ corticosteroids; NCS ¼ not using corticosteroids; MTX ¼ methotrexate;
HCQ ¼ hydroxychloroquine; RF ¼ rheumatoid factor; anti-CCP ¼ anti-cyclic citrullinated peptide antibody; DR4 ¼ HLA-DR4/þ antigen negative and positive; MMP3þ/ ¼ matrix metalloproteinase positive/negative; RFþ/ ¼
rheumatoid factor positive/negative; s ¼ subset; T ¼ treated; NT ¼ untreated; Data on HAQ progression are mean (SD) ¼ mean (stand deviation); β (95% CI) ¼ β-coefﬁcient (95% conﬁdence interval); unadj ¼ unadjusted; GEE ¼
generalised estimating equations; OLS ﬁxed effects ¼ ordinary least square; AUC ¼ area under curve.
a Fee for service.
b Managed care.
c HAQ score was not converted to a 0–3 score.
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charts [51,57]. Lassere et al. [51] constructed percentile charts
stratiﬁed by age, gender and disease duration. No overlap between
the 10th, 50th and 90th percentile curves was observed when
disease duration was included as a time-dependent variable. Wolfe
[33] focused on the identiﬁcation of distinct subgroups of patients
with similar progression patterns. In this study, changes at the
individual level were examined, observing that HAQ progression
did in general not follow a linear trend and could not be readily
categorised into distinct subgroups such as remitting, progressive
and ﬂuctuating.
In 2013, a novel approach to model individual HAQ progression
combined with a form of cluster analysis to identify groups with
similar trajectories was published by Norton et al. [24]. This study
identiﬁed four common progression subgroups. Since this
approach is novel and it is not clear whether the results are
generalisable, the following section shows the ﬁndings in which
this approach was repeated in the ERAS cohort, extending the
follow-up period to 15 years, and in NOAR.
Results of HAQ trajectories ERAS and NOAR cohorts
A total of 1460 ERAS patients and 1027 NOAR patients were
included in this study. The corresponding mean (SD) age was 55.2
(14.6) and 53.3 (15.9) years; and 67.1% and 64.8% were women
(Table 2). Although symptom duration was almost similar between
the two cohorts (8 months), compared to the NOAR population,
mean (SD) disease severity at baseline in the ERAS population was
slightly higher, i.e., the DAS28 score was 4.00 (1.43) compared to
5.46 (1.74) and the HAQ score was 0.87 (0.73) compared to 1.15
(0.77), respectively. Furthermore, more patients in ERAS fulﬁlled
the 1987 criteria for RA compared to patients in NOAR (70.6% vs
46.9%, respectively). These differences are probably a reﬂection of
the different referral criteria used for both the cohorts.
HAQ trajectories
A total of 1352 patients in ERAS and 830 patients in NOAR with
complete data on HAQ and covariates were included in the two
separate models. Independently, in both cohorts, a four-subgroup
LCGM was selected as providing the best ﬁt and most parsimony.
Although AIC or BIC preferred a larger number of subgroups, the
likelihood ratio test was in favour of a four-subgroup model
against a ﬁve (or more)-subgroup model. The subgroups identiﬁed
were similar in terms of the shape of the trajectories and the
distribution of patients between subgroups (Fig. 1). Three sub-
groups exhibited a J-shaped trajectory (subgroups: “low,” “moderate”Table 2
Demographic and clinical baseline characteristics of patients included in the ERAS
cohort and patients included in the NOAR cohort
% missing ERAS % missing NOAR
n ¼ 1460 n ¼ 1027
Age at onset, years 0 55.2 (14.6) 0 53.3 (15.9)
Gender, % female 0 67.1% 0 64.8%
Symptom duration, months 0 8.2 (7.6) 0 8.6 (9.2)
HAQ score 0.3 1.15 (0.77) 0 0.87 (0.73)
DAS28 score 0.9 5.46 (1.74) 18.9 4.00 (1.43)
Rheumatoid factor, % positive 1.0 72.7% 11.7 28.3%
ACR 1987 criteria for RA, % yes 0 70.6% 0 46.9%
Socio-economic status, % most
deprived
5.7 18.6% 0 12.5%
DMARDs 0 71.2% 0 16.4%
Values are mean (SD) for continuous variables or numbers (%) for categorical
variables. DAS28 ¼ 28 joint Disease Activity Score; HAQ ¼ Health Assessment
Questionnaire; DMARDs ¼ Disease-Modifying Anti-Rheumatic Drugs.and “high”). A fourth subgroup (“severe”) experienced persistently
high HAQ scores that increased early in the course of the disease
and remained during the 15-year follow-up period. The percentage
of patients allocated to each of the four subgroups was also very
similar between the two cohorts, ERAS and NOAR, respectively:
low (21.3% vs 21.2%); moderate (33.4% vs 31.9%); high (29.5% vs
26.5%); and severe (15.8% vs 20.3%). The percentage of patients
using methotrexate at any time during follow-up increased with
increasing subgroup of worse HAQ trajectory ranging from 27.8% in
the low subgroup membership group to 48.3% in the severe
subgroup in ERAS (Fig. 2). The percentage ranged from 8.9% to
38.2% in NOAR. In both the cohorts only 3.8% of patients received a
biologics during follow-up. The percentage of patients receiving
biologics was 5.3% in the severe subgroup of both cohorts, which
was lower than in the high subgroup, 5.9% and 7.7% in ERAS and
NOAR, respectively (Fig. 3).
Predictors of subgroup membership
In both ERAS and NOAR, older age, female gender and worse
DAS28 score were signiﬁcantly associated with increased like-
lihood of all subgroup memberships (low ¼ reference, moderate,
high and severe) of worse HAQ progression (Table 3). Although
less consistent across the cohorts, there was also a statistically
signiﬁcant association or a trend towards a positive association
between longer symptom duration, fulﬁlment of the 1987 ACR
criteria of RA and lower SES with higher risk class membership. No
association was found between RF and subgroup membership.
Actual model coefﬁcients are presented in Appendix.Discussion
This article gives an overview of the methods used to evaluate
HAQ changes over time in previous publications and shows the
results of a comparison study in two observational cohorts, ERAS
and NOAR, including patients with early IP and RA using a latent
class growth model. Across previously published studies, between
studies using the same database [eg, the USA National Data Bank
for Rheumatic Diseases (NDB)] but applying different statistical
methods, there was some variation in mean/median annual
change between the studies (ranging from 0.01 to 40.03), which
might partly be explained by differences in disease duration at
baseline, HAQ score at baseline, methods used to deal with missing
data of patients who were lost to follow-up or died or the
statistical methods used. Methods to assess change in HAQ scores
over time varied from cross-sectional analysis, calculating raw
change score and repeated measurement regression analysis. The
advantages of the latter analysis are that they model the sources of
variation and correlation that arise from, for example, observations
taken from the same subject at multiple time-points, violating
assumptions of within-subject independence. Most of these mod-
els are useful when assuming that in a given sample, individuals
are expected to change in the same direction across time with only
the degree of change varying between people. However, we know
from individual patient data that both the strength and the
direction of change are varying between patients. Wolfe [33]
identiﬁed three patterns of individual courses: patients who had
a high HAQ score at baseline and remained high, patients with
ﬂuctuating HAQ scores over time to be associated with variability
in inﬂammation and pain over time and patients who started low
and remained low. To address this problem, alternative modelling
strategies such as LCGM are available considering multi-nominal
heterogeneity in change. Another advantage of a LCGM is that it
can be used for incomplete longitudinal data either due to lost to
follow-up or due to intermittent missing data by assuming missing
01
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Fig. 2. Censored normal 4-class LCGM observed (- - -) and expected trajectories (–) of functional disability in NOAR and ERAS.
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mixture distribution offers a good ﬁt for non-normal distributed
outcomes such as HAQ. As far as we know, this is the ﬁrst time that
this model is used to independently identify similar common
trajectories of HAQ progression in patients with IP and RA in two
observational cohorts, ERAS and NOAR, following a large group of
patients with early IP and RA for 15 years. In both the cohorts, four
subgroups were identiﬁed showing very similar trajectories, i.e.,
patients who had a high HAQ score at baseline and did not
improve (severe subgroup), patients who had a low HAQ score,
improved and remained to have low HAQ scores over time (low
subgroup) and two classes with a similar pattern, but distinct
starting point (moderate and high subgroup). Age, gender, symp-
tom duration, the ACR 1987 criteria for RA, DAS28 score RF and SES
were included as indicators into the model. Of the demographic
and clinical variables, all but RF were signiﬁcant predictors for
identifying patients in one or more membership subgroups.
The results presented in this article are a ﬁrst step towards
personalised medicine, and these initial ﬁndings may further help0
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Fig. 3. Percentage of patients receiving methotrexate (A) or biologics (B)
during follow-up in each of the four class membership groups. —ERAS cohort
and —NOAR cohort.to develop probability scores of patients belonging to one of the
four groups. The information might also be useful in clinic to help
target therapy. In this study, we noticed, for example, that
compared to the high membership subgroup, the percentage of
patients using methotrexate was similar and the percentage of
patients using biologics was even lower in the severe subgroup,
suggesting that the patients in the severe subgroup need to be
treated more aggressively.
The identiﬁed predictors were very similar to those reported in
the publications reviewed in this article that investigated possible
predictors: older age [8,33,43,69], female gender [8,33,43,69],
disease duration [33,43] and disease activity [8]. Gardiner et al.
[19], however, did not ﬁnd an association between age, gender or
disease duration and change in HAQ score. Although concurrent
illness was associated with change in HAQ score in the latter study,
an observation seen in other studies as well [24,74,75], we were
not able to include co-morbidity as one of the indicators in our
models since co-morbidities were not reported consistently
between the two cohorts. For that reason we also did not include
radiographic joint damage, a predictor seen in some of the
reviewed studies. However, since both ERAS and NOAR include
patients with early IP or RA, the contribution of baseline radio-
graphic damage to identify subgroups would probably have been
minimal. Overall, identiﬁcation of the four subgroups and their
indicators is of importance when assessing patients with early RA
in clinic, and the information could be used to tailor treatment to
the individual patient.
There were also some limitations to this study. In the compar-
ison study, the referral criteria differed between the two cohorts,
resulting in patients recruited to ERAS having slightly higher
disease activity and more often being classiﬁed as having RA at
baseline compared to patients in NOAR. This discrepancy, however,
did not result in different models or identiﬁcation of different
predictors. Both IP and RA patients were included in both cohorts,
but this is probably also a reﬂection of a general arthritis
population seen in clinic.
The authors conclude that a diverse range of methods exists for
assessing the progression of disability in RA. As a consequence,
there is no appropriate way to combine previous published
research in the ﬁeld. However, the ERAS and NOAR cohorts
showed that HAQ progression could be placed into four HAQ
trajectory subgroups. These subgroups were nearly identical
between these cohorts, which supports their validity. Identifying
distinct groups of patients who are at risk of poor functional
outcome is likely to help target therapy to those who are most
likely to beneﬁt.
Table 3
Predictors of class membership in ERAS and NOAR
Class membership ERAS NOAR
Odds ratio z p 95% CI Odds ratio z p 95% CI
Age at onset
Low 1.00 1.00
Moderate 1.03 3.73 0.00 1.01–1.04 1.03 3.54 0.000 1.01–1.05
High 1.04 5.44 0.00 1.02–1.05 1.05 5.08 0.000 1.03–1.06
Severe 1.09 7.76 0.00 1.06–1.11 1.08 7.24 0.000 1.06–1.10
Female gender
Low 1.00 1.00
Moderate 2.32 4.30 0.000 1.58–3.40 2.38 3.42 0.001 1.45–3.92
High 5.44 7.93 0.000 3.58–8.28 2.76 3.76 0.000 1.63–4.68
Severe 7.21 7.34 0.000 4.26–12.22 8.21 6.32 0.000 4.28–15.76
Symptom duration, months
Low 1.00 1.00
Moderate 1.03 1.99 0.046 1.00–1.07 1.01 0.59 0.553 0.98–1.04
High 1.05 2.78 0.005 1.01–1.08 1.03 1.86 0.063 1.00–1.05
Severe 1.04 2.01 0.044 1.00–1.09 1.05 3.21 0.001 1.02–1.08
DAS28 score
Low 1.00 1.00
Moderate 1.36 3.81 0.000 1.16–1.59 1.48 3.42 0.001 1.18–1.85
High 1.77 7.50 0.000 1.53–2.06 1.87 5.34 0.000 1.48–2.35
Severe 2.23 9.26 0.000 1.88–2.63 3.17 8.50 0.000 2.43–4.13
Rheumatoid factor positive
Low 1.00 1.00
Moderate 1.24 0.90 0.368 0.78–1.97 1.47 1.19 0.233 0.78–2.78
High 1.37 1.26 0.207 0.84–2.24 1.58 1.44 0.151 0.84–2.97
Severe 1.35 1.03 0.304 0.76–2.38 2.36 2.42 0.016 1.18–4.73
The 1987 criteria for RA
Low 1.00 1.00
Moderate 1.32 1.24 0.216 0.85–2.05 1.23 0.64 0.524 0.66–2.29
High 1.51 1.75 0.081 0.95–2.40 2.20 2.53 0.011 1.19–4.06
Severe 2.56 2.97 0.003 1.38–4.75 2.04 2.01 0.044 1.02–4.10
Socio-economic status
Low 1.00 1.00
Moderate 2.70 2.71 0.007 1.32–5.53 1.42 0.78 0.433 0.59–3.38
High 3.06 3.27 0.001 1.56–5.98 3.07 2.72 0.007 1.37–6.91
Severe 4.17 3.75 0.000 1.98–8.81 3.43 2.61 0.009 1.36–8.66
DAS28 ¼ 28 joint Disease Activity Score; p ¼ p-value for statistical signiﬁcance; 95% CI ¼ 95% conﬁdence interval odds ratio.
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